PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24586874-5	2014	Lidocaine and bupivacaine caused disruption of mitochondrial membrane potential and release of cytochrome c, accompanied by activation of caspase 3 and 7, PARP cleavage, and induction of a higher ratio of Bax/Bcl-2.	Bupivacaine	14-25	BCL2 apoptosis regulator	Homo sapiens	209-214	
26621341-3	2016	Cultured human SH-SY5Y neuroblastoma cells were treated (bupivacaine) or untreated (control) with bupivacaine for 24 h. Compared to the control group, bupivacaine significantly increased cyto-inhibition, cellular reactive oxygen species, DNA damage, mitochondrial injury, apoptosis (increased TUNEL-positive cells, cleaved caspase 3, and Bcl-2/Bax), and activated autophagy (enhanced LC3II/LC3I ratio).	Bupivacaine	98-109	BCL2 apoptosis regulator	Homo sapiens	338-343	
26621341-3	2016	Cultured human SH-SY5Y neuroblastoma cells were treated (bupivacaine) or untreated (control) with bupivacaine for 24 h. Compared to the control group, bupivacaine significantly increased cyto-inhibition, cellular reactive oxygen species, DNA damage, mitochondrial injury, apoptosis (increased TUNEL-positive cells, cleaved caspase 3, and Bcl-2/Bax), and activated autophagy (enhanced LC3II/LC3I ratio).	Bupivacaine	98-109	BCL2 apoptosis regulator	Homo sapiens	338-343	
34151717-4	2021	The results showed that 1 mM Bupivacaine was available to signally inhibit CRC cell vitality, promoted apoptosis rate and apoptosis gene expression, like Bax, and caspase-3, inhibited Bcl-2 expression, inhibited cancer cell migration, promoted autophagy-related protein LC3B II/LC3B I ratio and beclin-1 expression, and inhibited p62 expression.	Bupivacaine	29-40	BCL2 apoptosis regulator	Homo sapiens	184-189	
35246010-10	2022	bupivacaine inhibited the expression of Bcl-2 and increased the expression of Bax and cytochrome C.	Bupivacaine	0-11	BCL2 apoptosis regulator	Homo sapiens	40-45